Literature DB >> 11583637

Exercise-induced myocardial perfusion abnormalities in sickle beta-thalassemia: Tc-99m tetrofosmin gated SPECT imaging study.

A Aessopos1, M Tsironi, I Vassiliadis, D Farmakis, A Fountos, E Voskaridou, A Perakis, S Defteraios, A Loutradi, D Loukopoulos.   

Abstract

PURPOSE: To determine the mechanism of myocardial ischemia in patients with sickle beta-thalassemia, we performed a scintigraphic evaluation of myocardial perfusion during exercise. SUBJECTS AND METHODS: We studied 30 patients with sickle beta-thalassemia, (mean [+/-SD] age, 37 +/- 10 years) who had no electrocardiographic (ECG), radiographic, or echo-Doppler signs of pulmonary hypertension, left ventricular hypertrophy, or impaired contractility. All patients had a hemoglobin level greater than 7 g/dL. Treadmill exercise test was performed according to the Bruce protocol. Myocardial perfusion was assessed by single-photon emission computed tomography, using Tetrofosmin Tc-99 m Myoview as radiotracer, at peak exercise and again 4 hours later.
RESULTS: Eight patients (27%) developed stress-induced scintigraphic perfusion abnormalities that were reversible in all but 1 patient. Subsequent coronary angiograms were normal in all 8 patients. ST segment depression was seen during exercise in 5 of the 7 patients who had reversible perfusion defects. Except for a significantly greater white blood cell count, these 5 patients did not differ from the rest of patients by sex, age, hemoglobin level, percentage hemoglobin F, beta-thalassemia genotype, or risk factors for coronary artery disease. Three of the 5 patients with perfusion and ECG abnormalities (and another with only perfusion defects) developed a stress-induced sickling crisis.
CONCLUSION: Physical stress may induce myocardial ischemia in sickle beta-thalassemia patients with normal coronary arteries and elicit painful crises. The sickling process, activated by exercise, could be the common underlying mechanism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583637     DOI: 10.1016/s0002-9343(01)00835-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

1.  Systolic and diastolic function in middle aged patients with sickle beta thalassaemia. An echocardiographic study.

Authors:  I Moyssakis; R Tzanetea; P Tsaftaridis; I Rombos; D P Papadopoulos; V Kalotychou; A Aessopos
Journal:  Postgrad Med J       Date:  2005-11       Impact factor: 2.401

2.  Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease.

Authors:  Courtney D Fitzhugh; Naudia Lauder; Jude C Jonassaint; Marilyn J Telen; Xiongce Zhao; Elizabeth C Wright; Francis R Gilliam; Laura M De Castro
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

3.  Speckle tracking evaluation of right ventricular functions in children with sickle cell disease.

Authors:  Osama Abd Rab Elrasol Tolba; Mohamed Ramadan El-Shanshory; Mohamed Abd Elaziz El-Gamasy; Walid Ahmed El-Shehaby
Journal:  Ann Pediatr Cardiol       Date:  2017 Sep-Dec

Review 4.  Advanced Echocardiography Techniques: The Future Stethoscope of Systemic Diseases.

Authors:  John Iskander; Peter Kelada; Lara Rashad; Doaa Massoud; Peter Afdal; Antoine Fakhry Abdelmassih
Journal:  Curr Probl Cardiol       Date:  2021-03-30       Impact factor: 16.464

5.  Evaluation of myocardial perfusion and function in patients with asymptomatic beta-thalassemia major using myocardial gated single-photon-emission computed tomography.

Authors:  Abdolmajid Omrani; Parivash Rahimzadeh; Ali Aba; Esmail Jafari; Abdullatif Amini; Majid Assadi
Journal:  World J Nucl Med       Date:  2020-12-12

Review 6.  Safety of maximal cardiopulmonary exercise testing in individuals with sickle cell disease: a systematic review.

Authors:  Kellsey N Smith; Tracy Baynard; Peter S Fischbach; Jane S Hankins; Lewis L Hsu; Peggy M Murphy; Kiri K Ness; Shlomit Radom-Aizik; Amy Tang; Robert I Liem
Journal:  Br J Sports Med       Date:  2021-07-20       Impact factor: 18.473

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.